5hvf - Revision history

OCA at 10:55, 16 August 2023

OCA — Wed, 16 Aug 2023 10:55:10 GMT

←Older revision		Revision as of 10:55, 16 August 2023
Line 3:		Line 3:
	<StructureSection load='5hvf' size='340' side='right'caption='[[5hvf]], [[Resolution\|resolution]] 2.85Å' scene=''>		<StructureSection load='5hvf' size='340' side='right'caption='[[5hvf]], [[Resolution\|resolution]] 2.85Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5hvf]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Alpaca Alpaca~~] and [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HVF OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://proteopedia.org/fgij/fg.htm?mol=5HVF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5hvf]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Vicugna_pacos Vicugna pacos]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HVF OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5HVF FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FLC:CITRATE+ANION'>FLC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene~~></td></tr>~~	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.85Å</td></tr>
-	~~<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5hvg\|5hvg]], [[5hvh\|5hvh]]</td></tr>~~	+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FLC:CITRATE+ANION'>FLC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CPB2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [https://pdbe.org/5hvf PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [https://www.ebi.ac.uk/pdbsum/5hvf PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5hvf ProSAT]</span></td></tr>
-	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carboxypeptidase_U Carboxypeptidase U], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.17.20 3.4.17.20] </span></td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://proteopedia.org/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [~~http~~://pdbe.org/5hvf PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/5hvf PDBsum], [~~http~~://prosat.h-its.org/prosat/prosatexe?pdbcode=5hvf ProSAT]</span></td></tr>	+
	</table>		</table>
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/CBPB2_HUMAN CBPB2_HUMAN]] Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.<ref>PMID:10574983</ref>	+	[https://www.uniprot.org/uniprot/CBPB2_HUMAN CBPB2_HUMAN] Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.<ref>PMID:10574983</ref>
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 25:		Line 23:
	*[[Antibody 3D structures\|Antibody 3D structures]]		*[[Antibody 3D structures\|Antibody 3D structures]]
	*[[Carboxypeptidase 3D structures\|Carboxypeptidase 3D structures]]		*[[Carboxypeptidase 3D structures\|Carboxypeptidase 3D structures]]
		+	*[[3D structures of non-human antibody\|3D structures of non-human antibody]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Alpaca]]~~	+	[[Category: Homo sapiens]]
-	~~[[Category: Carboxypeptidase U]]~~	+
-	~~[[Category: Human~~]]	+
	[[Category: Large Structures]]		[[Category: Large Structures]]
-	[[Category: ~~Declerck, P J~~]]	+	[[Category: Vicugna pacos]]
-	[[Category: ~~Strelkov, S V~~]]	+	[[Category: Declerck PJ]]
-	[[Category: ~~Weeks, S D~~]]	+	[[Category: Strelkov SV]]
-	[[Category: ~~Zhou, X~~]]	+	[[Category: Weeks SD]]
-	[[Category: ~~Antibody fragment]]~~	+	[[Category: Zhou X]]
-	~~[[Category: Hydrolase]]~~	+
-	~~[[Category: Hydrolase-hydrolase inhibitor complex]]~~	+
-	~~[[Category: Hydrolase/hydrolase inhibitor]]~~	+
-	~~[[Category: Nanobody]]~~	+
-	~~[[Category: Plasma procarboxypeptidase b]]~~	+
-	~~[[Category: Procarboxypeptidase r]]~~	+
-	~~[[Category: Procarboxypeptidase u]]~~	+
-	~~[[Category: Protein complex]]~~	+
-	~~[[Category: Tafi]]~~	+
-	~~[[Category: Thrombin-activatable fibrinolysis inhibitor~~]]	+

OCA at 08:33, 27 May 2020

OCA — Wed, 27 May 2020 08:33:38 GMT

←Older revision		Revision as of 08:33, 27 May 2020
Line 1:		Line 1:

	==Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)==		==Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)==
-	<StructureSection load='5hvf' size='340' side='right' caption='[[5hvf]], [[Resolution\|resolution]] 2.85Å' scene=''>	+	<StructureSection load='5hvf' size='340' side='right'caption='[[5hvf]], [[Resolution\|resolution]] 2.85Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[5hvf]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HVF OCA]. For a <b>guided tour on the structure components</b> use [http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5HVF FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[5hvf]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Alpaca Alpaca] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HVF OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=5HVF FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FLC:CITRATE+ANION'>FLC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FLC:CITRATE+ANION'>FLC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5hvg\|5hvg]], [[5hvh\|5hvh]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5hvg\|5hvg]], [[5hvh\|5hvh]]</td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">CPB2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carboxypeptidase_U Carboxypeptidase U], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.17.20 3.4.17.20] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carboxypeptidase_U Carboxypeptidase U], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.17.20 3.4.17.20] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [http://pdbe.org/5hvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [http://www.ebi.ac.uk/pdbsum/5hvf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5hvf ProSAT]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [http://pdbe.org/5hvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [http://www.ebi.ac.uk/pdbsum/5hvf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5hvf ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==
Line 20:		Line 21:
	</div>		</div>
	<div class="pdbe-citations 5hvf" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 5hvf" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
		+	*[[Carboxypeptidase 3D structures\|Carboxypeptidase 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
		+	[[Category: Alpaca]]
	[[Category: Carboxypeptidase U]]		[[Category: Carboxypeptidase U]]
		+	[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Declerck, P J]]		[[Category: Declerck, P J]]
	[[Category: Strelkov, S V]]		[[Category: Strelkov, S V]]

OCA at 02:27, 13 July 2016

OCA — Wed, 13 Jul 2016 02:27:05 GMT

←Older revision		Revision as of 02:27, 13 July 2016
Line 7:		Line 7:
	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5hvg\|5hvg]], [[5hvh\|5hvh]]</td></tr>		<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5hvg\|5hvg]], [[5hvh\|5hvh]]</td></tr>
	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carboxypeptidase_U Carboxypeptidase U], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.17.20 3.4.17.20] </span></td></tr>		<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carboxypeptidase_U Carboxypeptidase U], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.17.20 3.4.17.20] </span></td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [http://pdbe.org/5hvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [http://www.ebi.ac.uk/pdbsum/5hvf PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [http://pdbe.org/5hvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [http://www.ebi.ac.uk/pdbsum/5hvf PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5hvf ProSAT]</span></td></tr>
	</table>		</table>
	== Function ==		== Function ==

OCA at 23:11, 23 June 2016

OCA — Thu, 23 Jun 2016 23:11:50 GMT

←Older revision		Revision as of 23:11, 23 June 2016
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 5hvf is ~~ON HOLD~~ ~~until Paper~~ Publication	+	==Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)==
		+	<StructureSection load='5hvf' size='340' side='right' caption='[[5hvf]], [[Resolution\|resolution]] 2.85Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[5hvf]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5HVF OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5HVF FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=FLC:CITRATE+ANION'>FLC</scene>, <scene name='pdbligand=MAN:ALPHA-D-MANNOSE'>MAN</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr>
		+	<tr id='related'><td class="sblockLbl"><b>[[Related_structure\|Related:]]</b></td><td class="sblockDat">[[5hvg\|5hvg]], [[5hvh\|5hvh]]</td></tr>
		+	<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/Carboxypeptidase_U Carboxypeptidase U], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.4.17.20 3.4.17.20] </span></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5hvf FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5hvf OCA], [http://pdbe.org/5hvf PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5hvf RCSB], [http://www.ebi.ac.uk/pdbsum/5hvf PDBsum]</span></td></tr>
		+	</table>
		+	== Function ==
		+	[[http://www.uniprot.org/uniprot/CBPB2_HUMAN CBPB2_HUMAN]] Cleaves C-terminal arginine or lysine residues from biologically active peptides such as kinins or anaphylatoxins in the circulation thereby regulating their activities. Down-regulates fibrinolysis by removing C-terminal lysine residues from fibrin that has already been partially degraded by plasmin.<ref>PMID:10574983</ref>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	BACKGROUND: Thrombin-activatable fibrinolysis inhibitor (TAFI) is activated to TAFIa by thrombin, plasmin or by the thrombin-thrombomodulin (T/TM) complex. TAFIa is antifibrinolytic and high levels of TAFIa constitute an increased risk for cardiovascular disorders. TAFI inhibitory nanobodies represent a promising approach in developing profibrinolytic therapeutics. OBJECTIVE: To elucidate the molecular mechanisms of inhibition of TAFI activation and TAFIa activity by nanobodies using X-ray crystallography and biochemical characterization. METHODS AND RESULTS: We selected two nanobodies for co-crystallization with TAFI. VHH-a204 interferes with all TAFI activation modes, whereas VHH-i83 interferes with T/TM-mediated activation and also inhibits TAFIa activity. The 3.05 A resolution crystal structure of TAFI/VHH-a204 reveals that VHH-a204 epitope is localized to the catalytic moiety (CM) in close proximity to the TAFI activation site at Arg92, indicating that VHH-a204 inhibits TAFI activation by steric hindrance. The 2.85 A resolution crystal structure of TAFI/VHH-i83 reveals that the VHH-i83 epitope is located close to the presumptive TM-binding site in the activation peptide (AP). The structure and supporting biochemical assays suggest that VHH-i83 inhibits TAFIa by bridging the AP to the CM following TAFI activation. In addition, the 3.00 A resolution crystal structure of the triple TAFI/VHH-a204/VHH-i83 complex demonstrates that the two nanobodies can simultaneously bind to TAFI. CONCLUSIONS: This study provides detailed insights into the molecular mechanisms of TAFI inhibition and reveals a novel mode of TAFIa inhibition. VHH-a204 and VHH-i83 merit further evaluation as potential profibrinolytic therapeutics. This article is protected by copyright. All rights reserved.

-	~~Authors: Zhou~~, X., Weeks, ~~S.D.~~, Strelkov, S.V.~~, Declerck, P~~.J.	+	Elucidation of the molecular mechanisms of two nanobodies that inhibit TAFI activation and TAFIa activity.,Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ J Thromb Haemost. 2016 Jun 9. doi: 10.1111/jth.13381. PMID:27279497<ref>PMID:27279497</ref>

-	~~Description: Crystal Structure~~ of ~~Thrombin~~-~~activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH~~-~~i83)~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
		+	<div class="pdbe-citations 5hvf" style="background-color:#fffaf0;"></div>
		+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Carboxypeptidase U]]
		+	[[Category: Declerck, P J]]
		+	[[Category: Strelkov, S V]]
		+	[[Category: Weeks, S D]]
	[[Category: Zhou, X]]		[[Category: Zhou, X]]
-	[[Category: ~~Declerck, P.J~~]]	+	[[Category: Antibody fragment]]
-	[[Category: ~~Strelkov, S.V~~]]	+	[[Category: Hydrolase]]
-	[[Category: ~~Weeks, S.D~~]]	+	[[Category: Hydrolase-hydrolase inhibitor complex]]
		+	[[Category: Hydrolase/hydrolase inhibitor]]
		+	[[Category: Nanobody]]
		+	[[Category: Plasma procarboxypeptidase b]]
		+	[[Category: Procarboxypeptidase r]]
		+	[[Category: Procarboxypeptidase u]]
		+	[[Category: Protein complex]]
		+	[[Category: Tafi]]
		+	[[Category: Thrombin-activatable fibrinolysis inhibitor]]

OCA at 16:25, 26 February 2016

OCA — Fri, 26 Feb 2016 16:25:58 GMT

←Older revision		Revision as of 16:25, 26 February 2016
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 5hvf is ON HOLD	+	The entry 5hvf is ON HOLD until Paper Publication

	Authors: Zhou, X., Weeks, S.D., Strelkov, S.V., Declerck, P.J.		Authors: Zhou, X., Weeks, S.D., Strelkov, S.V., Declerck, P.J.

OCA: Protected "5hvf" [edit=sysop:move=sysop]

OCA — Wed, 03 Feb 2016 14:25:03 GMT

Protected "5hvf" [edit=sysop:move=sysop]

←Older revision

Revision as of 14:25, 3 February 2016

OCA: New page: '''Unreleased structure''' The entry 5hvf is ON HOLD Authors: Zhou, X., Weeks, S.D., Strelkov, S.V., Declerck, P.J. Description: Crystal Structure of Thrombin-activatable Fibrinolysis ...

OCA — Wed, 03 Feb 2016 14:25:01 GMT

New page: '''Unreleased structure''' The entry 5hvf is ON HOLD Authors: Zhou, X., Weeks, S.D., Strelkov, S.V., Declerck, P.J. Description: Crystal Structure of Thrombin-activatable Fibrinolysis ...

New page

'''Unreleased structure'''

The entry 5hvf is ON HOLD

Authors: Zhou, X., Weeks, S.D., Strelkov, S.V., Declerck, P.J.

Description: Crystal Structure of Thrombin-activatable Fibrinolysis Inhibitor in Complex with an Inhibitory Nanobody (VHH-i83)
[[Category: Unreleased Structures]]
[[Category: Zhou, X]]
[[Category: Declerck, P.J]]
[[Category: Strelkov, S.V]]
[[Category: Weeks, S.D]]